Post-Prostatectomy Surveillance

Recommended Monitoring Schedule

The National Comprehensive Cancer Network recommends PSA monitoring every 6 to 12 months for the first 5 years after radical prostatectomy, with more frequent testing (every 3 months) for men at high risk of recurrence 1, 2
After 5 years, PSA should be measured annually, and this annual monitoring should continue indefinitely 1, 2, 3

Biochemical recurrence is defined as PSA ≥ 0.2 ng/mL confirmed on two successive measurements, which is a widely accepted threshold in both research and clinical practice 4, 5
PSA should become undetectable (< 0.2 ng/mL) within several weeks of surgery, and any detectable or rising PSA indicates residual or recurrent disease 4, 6, 7

The National Comprehensive Cancer Network recommends annual digital rectal examination (DRE) to monitor for local recurrence and colorectal cancer, but the clinician may opt to omit DRE if PSA levels remain undetectable 1, 2
Early salvage therapy is most effective when initiated at lower PSA levels, and PSA doubling time < 6 months is associated with higher risk and need for intervention 5

The first PSA measurement should be taken 6 to 8 weeks after surgery, as earlier testing may yield falsely elevated results 1, 4, 6
High-risk patients (seminal vesicle invasion, positive margins, extraprostatic extension) require more intensive monitoring, with PSA checks every 3 months initially 1, 5

Imaging is generally not indicated unless PSA becomes detectable and rising (≥ 0.2 ng/mL on two occasions), and bone scans are rarely positive with PSA < 20-30 ng/mL 4, 6
Multiparametric MRI is most accurate for detecting local recurrence 4

Biochemical recurrence occurs in a substantial proportion of patients after radical prostatectomy and typically precedes clinical recurrence by several months to years, making serial PSA measurement the earliest marker of treatment failure. (Evidence level not specified) 8

The widely accepted definition of biochemical recurrence is a PSA level ≥ 0.2 ng/mL confirmed on two consecutive measurements; this criterion was used in 35 of 145 studies reviewed and is endorsed by the American Urological Association. (Evidence level not specified) 8
Although a PSA threshold of 0.4 ng/mL may better predict metastatic relapse risk, the 0.2 ng/mL cut‑point remains the standard for reporting outcomes and for triggering further evaluation. (Evidence level not specified) 8

When PSA rises on consecutive tests, calculation of PSA doubling time is recommended to assess the aggressiveness of recurrence. (Evidence level not specified) 8